Persistent URL of this record https://hdl.handle.net/1887/3633692
Documents
-
- Download
- 1-s2.0-S2468125322004344-main
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial
- All authors
- Linschoten, R.C.A. van; Jansen, F.M.; Pauwels, R.W.M.; Smits, L.J.T.; Atsma, F.; Kievit, W.; Jong, D.J. de; Vries, A.C. de; Boekema, P.J.; West, R.L.; Bodelier, A.G.L.; Gisbertz, I.A.M.; Wolfhagen, F.H.J.; Romkens, T.E.H.; Lutgens, M.W.M.D.; Bodegraven, A.A. van; Oldenburg, B.; Pierik, M.J.; Russel, M.G.V.M.; Boer, N.K. de; Mallant-Hent, R.C.; Borg, P.C.J. ter; Meulen-de Jong, A.E. van der; Jansen, J.M.; Jansen, S.V.; Tan, A.C.I.T.L.; Woude, C.J. van der; Hoentjen, F.; LADI Study Grp; Dutch Initiative Crohn and Colitis
- Date
- 2023-04-01
- Volume
- 8
- Issue
- 4
- Pages
- 343 - 355